Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06087029 · ClinicalTrials.gov registry record · NA

IMPRoving Outcomes in Vascular DisEase - Aortic Dissection

A NA study of Type B Aortic Dissection, sponsored by Duke University.

Recruiting
Registry status
NA
Development phase
1,100
Enrollment target
20
Study locations

NCT06087029 is a NA study of Type B Aortic Dissection that is actively recruiting participants, run by Duke University. The registered enrollment target is 1,100 participants. The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06087029, a NA study of Type B Aortic Dissection, is actively recruiting participants, sponsored by Duke University.

RECRUITING
Registry status
NA
Development phase
1,100 participants
Enrollment target
20
Study locations

Study Summary

The goal of this clinical trial is to determine whether an upfront invasive strategy of TEVAR plus medical therapy reduces the occurrence of a composite endpoint of all-cause death or major aortic complications compared to an upfront conservative strategy of medical therapy with surveillance for deterioration in patients with uncomplicated type B aortic dissection.

Conditions Studied

Interventions

  • PROCEDURE TEVAR
  • OTHER Guideline directed medical therapy and surveillance of dissection

Study Locations (20)

California

  • Memorial Care Long Beach Medical Center - Long Beach
  • Keck Medical Center of USC - Los Angeles
  • University of California San Diego - San Diego
  • University of California - San Francisco
  • Stanford University Medical Center - Stanford

Illinois

  • Northwestern University - Chicago
  • The University of Chicago - Chicago
  • Southern Illinois University School of Medicine - Springfield

Colorado

  • University of Colorado Denver - Aurora
  • Memorial Hospital Central - Colorado Springs

Connecticut

  • Hartford Hospital - Hartford
  • Yale University - New Haven

Florida

  • University of Florida Health - Gainesville
  • Tampa General Hospital - Tampa

Alabama

  • University of Alabama at Birmingham - Birmingham

Arizona

  • Honorhealth - Phoenix

Indiana

  • Indiana University Methodist Hospital - Indianapolis

Trial Details

FieldValue
Enrollment Target 1,100 participants
Start Date 2024-04-14
Est. Completion 2030-06-30
Phase NA

Sponsor

Duke University

1,725 total trials

What the Registry Record Tells You About NCT06087029

The ClinicalTrials.gov registry entry for NCT06087029 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 1,100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type B Aortic Dissection appearing as the primary indexed condition, and to 2 interventions - of which TEVAR is the first listed.

NCT06087029 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Illinois, Colorado.

Frequently Asked Questions

What is clinical trial NCT06087029 about?

NCT06087029 is a clinical study titled "IMPRoving Outcomes in Vascular DisEase - Aortic Dissection". The goal of this clinical trial is to determine whether an upfront invasive strategy of TEVAR plus medical therapy reduces the occurrence of a composite endpoint of all-cause death or major aortic complications compared to an upfront conservative strategy of medical therapy with surveillance for det...

What is the current status of trial NCT06087029?

This trial is currently recruiting. It is a NA study. The enrollment target is 1,100 participants. The study started on 2024-04-14. Estimated completion is 2030-06-30.

What conditions does trial NCT06087029 study?

This clinical trial studies the following conditions: Type B Aortic Dissection.

What interventions are being tested in trial NCT06087029?

The interventions under investigation include: TEVAR (PROCEDURE), Guideline directed medical therapy and surveillance of dissection (OTHER).

Who is sponsoring clinical trial NCT06087029?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06087029 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.